# CheckMate 744: HCP commentary report > 21 HCP sources screened · 197 verified claims from 21 sources · 7 findings. Updated 2026-10-09. ## Report - Trial: Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation) - NCT ID: NCT02927769 - Registry: https://clinicaltrials.gov/study/NCT02927769 - Sponsor: Bristol-Myers Squibb - Phase: Phase 2 - Status: Completed - Drugs: nivolumab, brentuximab vedotin, bendamustine - Indications: Hodgkin lymphoma - Version: v1.0.0, edition 1 - Accepted: 2026-10-09 - Last checked: 2026-10-09 - Release hash: d8668b9245b2cc01a6e8a67fde3a2abf1444a1d51319e110374710fd7034c9a1 ## Counts - HCP commentary sources screened: 21 - Sources cited by verified claims: 21 - Verified claims: 197 - Findings: 7 - People found in screened sources: 30 - People identity-verified: 28 - Voices cited: 21 Counts describe the retained sources. They do not estimate how many HCPs hold a view. ## Abstract CheckMate 744 anchors clinicians’ discussion of which children, adolescents and young adults with relapsed or refractory classical Hodgkin lymphoma might be treated without an autologous stem-cell transplant. Topics include response-guided treatment selection, PET imaging and investigational ctDNA, radiotherapy’s place in salvage care, endpoints and evidence needed for transplant omission, and translation to adult practice. Clinicians also discuss prior treatment exposure, drug access, long-term toxicity, fertility, survivorship support and family involvement in treatment decisions. Coverage is limited to the supplied commentary sources. ## Open Medical Affairs question How should scientific exchange distinguish a selected transplant-sparing option from an off-trial replacement for autograft? ## Findings (titles) - F1. Selective transplant avoidance is welcomed, but enthusiasm does not equal abandonment of autograft - F2. Modern ISRT is being rehabilitated through a total-treatment toxicity argument - F3. The evidence threshold is durable omission with a credible later-salvage strategy - F4. PET-based selection is practical; ctDNA remains a proposed refinement rather than a validated omission rule - F5. Access, prior exposure and relapse timing can override an otherwise attractive regimen - F6. Reducing intensity does not remove the need for fertility, cardiology and lifelong survivorship support - F7. Family fear of relapse can favor familiar intensive treatment despite the appeal of de-escalation ## Sample findings ### F3. The evidence threshold is durable omission with a credible later-salvage strategy In discussion of CheckMate 744 on X, a speaker asked whether transplant-free survival should be added as an endpoint. Source: X thread, 2023-10-01. ### F4. PET-based selection is practical; ctDNA remains a proposed refinement rather than a validated omission rule In a podcast discussion of CheckMate 744, the host asked how imaging, including PET, informs patient selection, treatment choice and duration. Source: podcast, 2025-04-17. ## Trial aspects | Aspect | Coverage | Claims | Sources | | --- | --- | ---: | ---: | | Primary endpoint: Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1 | discussed | 4 | 4 | | Primary endpoint: Event-free Survival (EFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) - Cohort 1 | discussed | 2 | 2 | | Primary endpoint: Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Blinded Independent Centralized Review (BICR) - Cohort 2 | no commentary found | 0 | 0 | | Secondary endpoints | discussed | 13 | 11 | | Population and setting | discussed | 19 | 14 | | The comparison | discussed | 9 | 8 | | Safety and tolerability | discussed | 18 | 10 | | Design and conduct | discussed | 7 | 7 | | Risk selection, PET and investigational ctDNA | discussed | 21 | 3 | | Selective transplant omission versus routine-care autograft | discussed | 22 | 5 | | Modern ISRT contribution, planning and transplant-free endpoints | discussed | 17 | 8 | | Alternative salvage strategies and the evidence threshold for omission | discussed | 22 | 6 | | Pediatric-to-adult translation and evidence-generation models | discussed | 8 | 4 | | UK access, prior exposure and relapse-dependent sequencing | discussed | 21 | 4 | | Fertility, cardiovascular follow-up and lifelong survivorship | discussed | 18 | 3 | | Family preferences, adolescent involvement and planning time | discussed | 7 | 1 | ## Cited sources by channel - Podcasts: 3 - Publications: 1 - Registry: 1 - X threads: 14 - YouTube: 2 ## Scope and limits This report does not judge efficacy, estimate HCP prevalence or consensus, give treatment advice. - Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing. - 6 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up. - 4 further source limits are recorded in the machine-readable scope of this record. - The reviewed material is not a census of HCP opinion. Some unnamed or differently transcribed trial discussions may be absent, and one potentially relevant video was inaccessible. - Several posts concern the same presentation, and audio/video versions contain overlapping remarks. Their number cannot establish independent clinical agreement or adoption. - Full text of the low-risk publication was unavailable; supplied abstract and registry context do not turn shared headlines or speaker summaries into independently established clinical conclusions. - Risk groups, endpoints, timepoints and subsequent therapies differ across the studies and summaries discussed. In particular, standard-risk R2 is transplant-based, and attributed low-risk outcome summaries should not be pooled or silently relabeled. - Long-term comparative toxicity and the consequences of checkpoint exposure in young patients remain uncertain in the commentary; favorable acute tolerability does not resolve them. - Professional context for Cathy Burton is incomplete in the supplied profile. Source naming supports attribution of the remarks, not additional claims about employment, credentials or current practice authority. ## Offer - Size: Standard (19 commentary sources cited) - Current edition: $1,250. Buy it below; a purchase starts a check for new commentary and any newer edition follows at no charge - 3 months of weekly updates: $2,200 - 6 months of weekly updates: $3,100 - 12 months of weekly updates: $4,400 - Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (28 now), at most $1,250; people verified later in the term at no charge - Pricing: https://www.erudio.com/pricing - Buy now (card, through Stripe): https://www.erudio.com/reports/checkmate-744-nct02927769 - Agents: POST https://www.erudio.com/api/orders with {"report": "checkmate-744-nct02927769", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": ""}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your licence key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again - Talk to Tom and Audun (invoice, PO, questions): https://www.erudio.com/contact?report=checkmate-744-02927769 ## Cite Erudio Health. CheckMate 744 (NCT02927769): HCP commentary report. Edition 1, v1.0.0. Accepted 2026-10-09. https://www.erudio.com/reports/checkmate-744-nct02927769 ## Machine access - JSON: https://www.erudio.com/reports/checkmate-744-nct02927769.json - MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "checkmate-744-02927769"}`